Exelixis (EXEL) is back in focus after new subgroup data from the phase 3 CABINET trial showed that CABOMETYX improved progression-free survival versus placebo in advanced neuroendocrine tumor patients across both non-functional and functional groups.

The share price has moved to US$52.99 after a 26.92% 90 day share price return and a 24.62% 1 year total shareholder return, with momentum building alongside the CABINET data and recent conference and pipeline updates.

If this cancer data has you thinking about where drug development could head next, it may be a good time to scan other healthcare AI opportunities using the 39 healthcare AI stocks

With Exelixis now at US$52.99 after strong recent returns and an intrinsic value estimate that still sits well below the market price, the key question is whether there is still an opportunity here or if the stock already reflects future growth.

Most Popular Narrative: 7% Overvalued

At US$52.99 the most followed narrative pegs Exelixis' fair value closer to US$49.65, which puts current pricing slightly ahead of that view.

The company's substantial free cash flow, strong balance sheet, and disciplined capital allocation (including aggressive share repurchases and prioritization of high-probability, high-value R&D programs) position Exelixis to invest in next-generation discovery and strategic partnerships, which has the potential to improve operating leverage and net margins over time as the product portfolio scales.

Curious what kind of revenue path, margin profile and future earnings multiple need to line up to reach that fair value mark? The narrative spells out a tight set of assumptions on growth, profitability and valuation compression that underpin the current model without relying on highly optimistic forecasts.

Result: Fair Value of $49.65 (OVERVALUED)

However, the heavy reliance on CABOMETYX for over 90% of revenue, along with the potential impact of pricing pressure and 340B discounts, could quickly challenge that fair value story.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another Take: Big Gap To DCF Fair Value

While analyst targets cluster near US$49.65 and frame Exelixis as roughly 7% overvalued, the SWS DCF model presents a very different picture. It indicates a future cash flow value of about US$216.59 per share, or roughly 75.5% above the current US$52.99 price. This raises the question: which lens do you trust more?

Next Steps

With sentiment split between upside potential and valuation risk, it makes sense to move quickly, test the numbers yourself, and see whether the balance of concerns and optimism fits your own risk tolerance by reviewing the 4 key rewards and 1 important warning sign

Looking for more investment ideas?

If Exelixis has sharpened your focus, do not stop here. Widen your watchlist now so you are not catching up after the next move breaks out.

• Target potential value opportunities early by scanning 46 high quality undervalued stocks that combine quality fundamentals with prices that differ from intrinsic value estimates.
• Strengthen your income stream by reviewing 9 dividend fortresses that pair higher yields with businesses focused on sustaining payouts.
• Prioritise resilience by checking 63 resilient stocks with low risk scores that score well on balance sheet strength and volatility.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.